Phenotypic characteristics of the 122 patients whose biopsy has been hybridized on microarrays
Patients Preliminary group Validation group . | Total N = 122 93 29 . | B-CLL/SLL n = 31 . | . | Splenic MZL*n = 37 . | . | MCL n = 56 . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| . | . | Preliminary group, n = 19 (%) . | Validation group, n = 10 (%) . | Preliminary group, n = 29 (%) . | Validation group, n = 8 (%) . | Preliminary group, n = 45 (%) . | Validation group, n = 11 (%) . | |||
| Samples | ||||||||||
| Lymph node | 77 (63) | 19 (100) | 9 (90) | 2 (6)† | 0 | 38 (85) | 9 (82) | |||
| Spleen | 33 (27) | 0 | 1 (10) | 19 (66) | 8 (100) | 5 (11) | 0 | |||
| Blood | 9 (7) | 0 | 0 | 8 (28) | 0 | 1 (2) | 0 | |||
| Others: tonsil | 3 (3) | 0 | 0 | 0 | 0 | 1 (2) | 2 (18) | |||
| Immunophenotype | 122 (100) | |||||||||
| CD19/CD20+ | 19 (100) | 9 (100) | 29 (100) | 8 (100) | 38 (100) | 9 (100) | ||||
| CD5+ | 19 (100) | 9 (100) | 5 (17) | 0 | 35 (92) | 9 (100) | ||||
| CD23+ | 19 (100) | 9 (100) | 0 | 0 | 0 | 0 | ||||
| CD43+ | 19 (100) | 9 (100) | 0 | 0 | 38 (100) | 9 (100) | ||||
| CD10+ | 0 | 0 | 0 | 0 | — | — | ||||
| Cytogenetic features | 96 (79) | 19 | 2 | 29 | 2 | 34 | 2 | |||
| del 13q | 1 (5) | 0 | 1 (3) | 0 | 0 | 0 | ||||
| +12 | 9 (47) | 0 | 0 | 0 | 0 | 0 | ||||
| del 11q | 4 (21) | 0 | 0 | 0 | 1 (3) | 0 | ||||
| +3 or +3q | 0 | 0 | 8 (27) | 0 | 2 (6) | 0 | ||||
| del 7q | 0 | 0 | 5 (17) | 0 | 0 | 0 | ||||
| t(11;14) | 0 | — | 2 (11) | 0/2 | 34/34 (100) | 2/2 (100) | ||||
| Molecular features | ||||||||||
| Cyclin D1 +++ | 58 (46) | — | — | 2 (11) | 0 | 45 (100) | 9 (100) | |||
| Ig mutation status | ||||||||||
| Mutated (<98) | 36 (29) | 5 (26) | 1 (10) | 19 (66) | 4 (50) | 7 (15) | 0 | |||
| Unmutated (≥ 98%) | 63 (52) | 12 (63) | 8 (80) | 8* (27) | 4 (50) | 22 (49) | 9 (82) | |||
| Not done | 23 (19) | 2 (11) | 1 (10) | 2 (7) | 0 | 16 (36) | 2 (8) | |||
| Circulating peripheral | ||||||||||
| blood lymphoma | ||||||||||
| cells > 10 × 109/L | 2/19 (10) | 0/8 | 13 (45) | 0/6 | 1/45 | 0/7 | ||||
Patients Preliminary group Validation group . | Total N = 122 93 29 . | B-CLL/SLL n = 31 . | . | Splenic MZL*n = 37 . | . | MCL n = 56 . | . | |||
|---|---|---|---|---|---|---|---|---|---|---|
| . | . | Preliminary group, n = 19 (%) . | Validation group, n = 10 (%) . | Preliminary group, n = 29 (%) . | Validation group, n = 8 (%) . | Preliminary group, n = 45 (%) . | Validation group, n = 11 (%) . | |||
| Samples | ||||||||||
| Lymph node | 77 (63) | 19 (100) | 9 (90) | 2 (6)† | 0 | 38 (85) | 9 (82) | |||
| Spleen | 33 (27) | 0 | 1 (10) | 19 (66) | 8 (100) | 5 (11) | 0 | |||
| Blood | 9 (7) | 0 | 0 | 8 (28) | 0 | 1 (2) | 0 | |||
| Others: tonsil | 3 (3) | 0 | 0 | 0 | 0 | 1 (2) | 2 (18) | |||
| Immunophenotype | 122 (100) | |||||||||
| CD19/CD20+ | 19 (100) | 9 (100) | 29 (100) | 8 (100) | 38 (100) | 9 (100) | ||||
| CD5+ | 19 (100) | 9 (100) | 5 (17) | 0 | 35 (92) | 9 (100) | ||||
| CD23+ | 19 (100) | 9 (100) | 0 | 0 | 0 | 0 | ||||
| CD43+ | 19 (100) | 9 (100) | 0 | 0 | 38 (100) | 9 (100) | ||||
| CD10+ | 0 | 0 | 0 | 0 | — | — | ||||
| Cytogenetic features | 96 (79) | 19 | 2 | 29 | 2 | 34 | 2 | |||
| del 13q | 1 (5) | 0 | 1 (3) | 0 | 0 | 0 | ||||
| +12 | 9 (47) | 0 | 0 | 0 | 0 | 0 | ||||
| del 11q | 4 (21) | 0 | 0 | 0 | 1 (3) | 0 | ||||
| +3 or +3q | 0 | 0 | 8 (27) | 0 | 2 (6) | 0 | ||||
| del 7q | 0 | 0 | 5 (17) | 0 | 0 | 0 | ||||
| t(11;14) | 0 | — | 2 (11) | 0/2 | 34/34 (100) | 2/2 (100) | ||||
| Molecular features | ||||||||||
| Cyclin D1 +++ | 58 (46) | — | — | 2 (11) | 0 | 45 (100) | 9 (100) | |||
| Ig mutation status | ||||||||||
| Mutated (<98) | 36 (29) | 5 (26) | 1 (10) | 19 (66) | 4 (50) | 7 (15) | 0 | |||
| Unmutated (≥ 98%) | 63 (52) | 12 (63) | 8 (80) | 8* (27) | 4 (50) | 22 (49) | 9 (82) | |||
| Not done | 23 (19) | 2 (11) | 1 (10) | 2 (7) | 0 | 16 (36) | 2 (8) | |||
| Circulating peripheral | ||||||||||
| blood lymphoma | ||||||||||
| cells > 10 × 109/L | 2/19 (10) | 0/8 | 13 (45) | 0/6 | 1/45 | 0/7 | ||||
Blood samples were used for microarray hybridization when frozen material (spleen biopsy [n = 8] for splenic MZL or node biopsy [n = 1] for MCL) was not available for RNA extraction. All blood samples contained more than 50% lymphoma cells.—indicates not done.
bcl-6 immunostaining was negative.
Two patients presented a nodal MZL and not splenic MZL at diagnosis.